ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Pulmonary and systemic inflammation plays a key role in the prognosis of patients with acute lung injury ALI. Lipopolysaccharide (LPS)-induced ALI is a classical model to study new treatments for ALI. Here, Escherichia coli LPS (026:B6; L3755, Sigma Aldrich, St. Louis, MO, USA) were administered intra-peritoneally (i.p.) in male C57Bl/6 mice to induce ALI. Control (n=12), Virlaza (50ul intra-nasally; n=12), LPS (100ug i.p.; n=12) and LPS+Virlaza (100ug i.p. +50ul intra-nasally; n=12) were studied. The results demonstrated that Virlaza reduced the number of total leukocytes (p<0.01), neutrophils (p<0.01), lymphocytes (p<0.01) and macrophages (p<0.01) in the bronchoalveolar lavage (BAL), while also reduced the BAL levels of IL-1beta (p<0.01), IL-6 (<0.01), CXCL1/KC (p<0.01), IL-17 (p<0.01) and TNF-alpha (p<0.01). Virlaza increased the levels of anti-inflammatory cytokine IL-10 (p<0.001). Virlaza reduced the accumulation of neutrophils (p<0.05), lymphocytes (p<0.05) and macrophages (p<0.05) in the lung parenchyma. In addition, Virlaza also inhibited LPS-induced systemic inflammation, as denoted by reduced number of total leukocytes (p<0.01), neutrophils (p<0.001), lymphocytes (p<0.05), and monocytes (p<0.01). Of note, Virlaza also reduced the serum levels of IL-1beta (p<0.05), IL-6 (<0.001), CXCL1/KC (p<0.05), IL-17 (p<0.001) and TNF-alpha (p<0.001), while increased the levels of IL-10 (p<0.001). Thus, we conclude that Virlaza possesses potent pulmonary and systemic anti-inflammatory effects against bacterial infection, which deserves further clinical trials to confirm such pre-clinical findings.

Abstract

#{title}